Biogen (BIIB.US) Q3 results beat expectations, with strong sales of rare disease drugs.

Zhito Finance APP has learned that Biogen (BIIB.US) released its third-quarter results before the market opened on October 28: total revenue was US$2.804 billion, up 11% year over year, or 10% growth at constant currency, higher than the market expectation of US$2.63 billion to US$2.68 billion; adjusted diluted earnings per share were US$2.62, above the expected approximately US$1.99, but down 46% year over year. Strong demand for the company's rare disease and Alzheimer's disease drugs helped offset the impact of declining sales of multiple sclerosis treatments.